鸡γ干扰素成熟蛋白基因的表达及其产物抗病毒活性测定

以血淋巴细胞提取的总RNA为模板,通过RT-PCR的方法克隆出鸡干扰素成熟蛋白的基因,把它与非融合表达载体pRLC相重组。通过对阳性宿主菌的不同时间的诱导摸索出最佳表达时间。把表达产物进行变性,复性,纯化后加入鸡胚成纤维细胞上,用水疱性口炎病毒进行攻毒,测出鸡重组干扰素的活性单位为1.0?06U/mL,获得了满意结果。     

SARS—CoVSars7a和EGFP融合蛋白真核表达载体构建及其表达

根据SARS-CoV sars7a基因设计并化学合成部分重叠引物,经二轮PCR获得sars7a基因片段,以此片段为模板并利用一对带有Kozak序列及删除终止密码的引物进行PCR,获得产物与pEGFP-N1载体连接,使sars7a基因位于．EGFP的基因上游,得到含编码Sars7a-EGFP融合蛋白基因的哺乳动物细胞表达载体。采用细胞核转染技术将重组表达载体转染K562细胞,以流式细胞仪和共聚焦显微镜分析,可检测到EGFP的绿色荧光,表明Sars7a—EGFP得到表达,该蛋白分布于整个细胞,提示Sars7a并非膜蛋白,更可能是胞浆蛋白。此外,该蛋白的表达对K562细胞凋亡无明显影响。     

白斑综合症病毒囊膜蛋白VP19、VP28的融合表达及中和抗体的制备

根据GenBank上WSSV囊膜蛋白基因vp19和vp28的序列,设计并合成两对引物,PCR扩增得到vp19和vp28两基因,大小分别为370bp和630bp。通过EcoRI位点连接两基因,再按正确的阅读框插入表达载体pET-22b( )中,构建出重组表达载体pET-vp(19 28)并转化大肠杆菌BL21(DE3)。基因工程菌株35℃IPTG诱导,表达产物经SDS-PAGE检测显示有与预期大小41kDa相吻合的融合蛋白带。用Ni^2 -柱纯化的基因工程蛋白免疫新西兰大白兔制备抗血清,进行螯虾活体中和病毒实验,结果表明抗血清对WSSV的中和效率达到了100％。     

对虾白斑综合征病毒ORF220基因在昆虫细胞内的表达及其分布

对虾白斑综合征病毒厦门分离株ORF220编码真核生物GP130受体同源蛋白。将ORF220和绿色荧光蛋白编码基因融合在一起克隆到昆虫杆状病毒表达载体pFastBacI,然后与AcBacmid共同转染DH10B细胞。用PCR鉴定含有ORF220和EGFP基因的重组质粒,提取纯化重组质粒并转染昆虫细胞进行表达。结果发现,DNA转染后3-5d可以在荧光显微镜下观察到绿色荧光,表明融合蛋白在昆虫系统内成功表达。用病毒上清液感染昆虫细胞进行时相观察,结果表明,ORF220蛋白在昆虫细胞的细胞质和细胞核内呈随机分布,没有特异的细胞定位。     

地鼠肾细胞狂犬病纯化疫苗临床研究观察

了解地鼠肾细胞狂犬病纯化疫苗接种安全性及有效性。分别以 1.0ml及 0 .5ml的剂量 ,按暴露后及暴露前免疫程序给 313人接种 ,用小鼠中和试验法检测血清中和抗体效价。结果显示 :临床副反应轻微 ,副反应率为0 .89%～ 15 % ;免疫全量疫苗和半量疫苗的人群均获保护力 ,抗体阳转率为 10 0 % ,免后抗体GMT滴度分别为35 .2IU/ml(n =32 )和 31.4IU/ml(n =37) ,经检验两组无显著性差异 (P>0 .0 5 ) ;免疫全量疫苗和半量疫苗两组的免疫前、后相比 ,经检验有显著性差异 (P <0 .0 5 ) ,表明疫苗安全有效     

应用多聚酶链式反应快速分析FMR-1基因突变

为了建立一种在先天性智力低下患儿中快速分析脆性X综合征智力低下基因1(Fragile X mental retardation gene 1.FMR-1)突变的方法,对先天性智力低下儿童进行脆性X综合征的大面积筛查和诊断,应用复式多聚酶链式反应一次性扩增FMR-1基因的(CGG)n的重复区,分析CGG重复序列的大小,判断FMR-1基因状态(正常、突变前、突变后),对脆性X综合征可疑患儿快速筛查,在113倒不明原因的先天性智力低下患儿中,分析有脆性X综合征携带者(FMR-1基因前突变者)7例(2男5女),脆性X综合征患者(FMR-1基因突变者)5例,应用多聚酶链式反应可以对脆性X综合征可疑患儿进行大面积初筛,确定携带者和患者。     

Current perspectives in pulmonary surfactant — Inhibition, enhancement and evaluation

Pulmonary surfactant (PS) is a complicated mixture of approximately 90% lipids and 10% proteins. It plays an important role in maintaining normal respiratory mechanics by reducing alveolar surface tension to near-zero values. Supplementing exogenous surfactant to newborns suffering from respiratory distress syndrome (RDS), a leading cause of perinatal mortality, has completely altered neonatal care in industrialized countries. Surfactant therapy has also been applied to the acute respiratory distress syndrome (ARDS) but with only limited success. Biophysical studies suggest that surfactant inhibition is partially responsible for this unsatisfactory performance. This paper reviews the biophysical properties of functional and dysfunctional PS. The biophysical properties of PS are further limited to surface activity, i.e., properties related to highly dynamic and very low surface tensions. Three main perspectives are reviewed. (1) How does PS permit both rapid adsorption and the ability to reach very low surface tensions? (2) How is PS inactivated by different inhibitory substances and how can this inhibition be counteracted? A recent research focus of using water-soluble polymers as additives to enhance the surface activity of clinical PS and to overcome inhibition is extensively discussed. (3) Which in vivo, in situ, and in vitro methods are available for evaluating the surface activity of PS and what are their relative merits? A better understanding of the biophysical properties of functional and dysfunctional PS is important for the further development of surfactant therapy, especially for its potential application in ARDS.     

Functional studies on three novel HCNH2 mutations in Taiwan: identification of distinct mechanisms of channel defect and dissociation between glycosylation defect and assembly defect

Mutations of the KCNH2 with decreased channel activity lead to congenital long QT syndrome (LQTS). We studied the electrophysiological, glycosylation, trafficking and assembly properties of three novel KCNH2 mutations identified in Taiwanese patients with LQTS (p.N633D, p.R744fs, and p.P923fs). When expressed in HEK293T cells, p.N633D and p.R744fs HERG channels displayed no HERG current while p.P923fs HERG channel showed HERG current with significantly lower (34%) current density and faster inactivation kinetics. In Western blot analysis, pR744fs was the only one with glycosylation defect, which was in consistence with the confocal microscopic findings showing that p.R744fs-GFP was the only one with trafficking defect. However, p.R744fs-GFP differed from pR744fs in being fully glycosylated while p.R744fs fusion with GFP at the N-terminus revealed glycosylation defect. To access the assembly capacity of each mutant, co-immunoprecipitation was conducted. Wild type (WT), p.N633D, and p.P923fs HERG protein showed assembly ability while p.R744fs failed to assemble with neither WT nor itself.In conclusion, we identified three novel LQTS-related KCNH2 mutations and each had a distinct mechanism of channel defect. For p.R744fs mutant, adding GFP to the C-terminus rescued the glycosylation defect but the channel was still assembly defective indicating a dissociation between glycosylation and assembly defects.     

Novel mutations in the adipose triglyceride lipase gene causing neutral lipid storage disease with myopathy

A subgroup of neutral lipid storage disease has been recently associated with myopathy (NLSDM) and attributed to mutations in the gene (PNPLA2) encoding an adipose triglyceride lipase involved in the degradation of intracellular triglycerides. Five NLSDM patients have been described thus far and we reported three additional patients. A 44-year old Iranian woman and two Italian brothers, aged 40 and 35, presented with exercise intolerance and proximal limb weakness, elevated CK levels, and Jordan’s anomaly. Muscle biopsies showed marked neutral lipid accumulation in all patients. The 10 exons and the intron-exon junctions of the PNPLA2 gene were sequenced. Two novel homozygous mutations in exon 5 of PNPLA2 gene were found (c.695delT and c.542delAC). Both mutations resulted in frameshifts leading to premature stop codons (p.L255X and p.I212X, respectively). These mutations predict a truncated PNPLA2 protein lacking the C-terminal hydrophobic domain. These findings indicate that NLSDM is rare, but genetically heterogeneous.     

A novel site-specific recombination system derived from bacteriophage phiMR11

We report identification of a novel site-specific DNA recombination system that functions in both in vivo and in vitro, derived from lysogenic Staphylococcus aureus phage phiMR11. In silico analysis of the phiMR11 genome indicated orf1 as a putative integrase gene. Phage and bacterial attachment sites (attP and attB, respectively) and attachment junctions were determined and their nucleotide sequences decoded. Sequences of attP and attB were mostly different to each other except for a two bp common core that was the crossover point. We found several inverted repeats adjacent to the core sequence of attP as potential protein binding sites. The precise and efficient integration properties of phiMR11 integrase were shown on attP and attB in Escherichia coli and the minimum size of attP was found to be 34bp. In in vitro assays using crude or purified integrase, only buffer and substrate DNAs were required for the recombination reaction, indicating that other bacterially encoded factors are not essential for activity.